10-Q: H.B. Fuller Q3 Earnings Rise Amid Strategic Acquisitions

H.B. Fuller Company reported a 21.3% increase in net income and a 24.5% rise in diluted EPS for the third quarter of 2025, driven by improved gross profit margins and strategic acquisitions, despite a slight revenue decline.

Summary

• Net income attributable to H.B. Fuller increased 21.3% to $67.2 million in Q3 2025, up from $55.4 million in Q3 2024.
• Diluted earnings per share rose 24.5% to $1.22 in Q3 2025, compared to $0.98 in Q3 2024.
• Gross profit margin expanded by 200 basis points to 32.0% in Q3 2025, primarily due to higher product pricing, lower distribution costs, and the impact of acquisitions/divestitures.
• Net revenue for Q3 2025 decreased 2.8% to $892.0 million, influenced by a 2.9% decrease from acquisitions/divestitures (net of NA Flooring sale) and a 1.9% decrease in sales volume, partially offset by a 1.0% increase from pricing and a 1.0% positive currency effect.
• For the first nine months of 2025, net income attributable to H.B. Fuller decreased 11.2% to $122.2 million, and diluted EPS fell 9.0% to $2.21.
• Net cash provided by operating activities for the first nine months of 2025 was $156.8 million, a decrease from $216.8 million in the same period of 2024.
• Free cash flow for the first nine months of 2025 was $62.2 million, down from $104.0 million in the prior year period.
• The company completed several acquisitions, including ND Industries Asia, Inc. for approximately $8.31 million, GEM S.r.l. and Medifill Limited for a total of approximately $197.0 million, and HS Butyl Limited for approximately $23.4 million.
• The North American Flooring business was divested for $75.7 million, resulting in a $1.5 million loss.
• Restructuring plans, initiated in fiscal year 2023, are expected to be completed in fiscal year 2026, with $69.7 million in costs incurred to date out of an estimated $70.0 million to $75.0 million.

Sentiment

Score: 6

Explanation: While the third quarter showed strong year-over-year growth in net income and EPS, driven by improved gross margins and strategic acquisitions, the year-to-date performance reflects a decline in net income, EPS, and particularly in operating and free cash flow. The company is actively managing its portfolio through acquisitions and divestitures and has successfully refinanced debt, indicating proactive financial management. However, the overall revenue decline and reduced cash generation for the nine-month period present a mixed picture.

Positives

• Net income attributable to H.B. Fuller increased by 21.3% to $67.2 million in Q3 2025 compared to Q3 2024.
• Diluted earnings per share rose by 24.5% to $1.22 in Q3 2025 compared to Q3 2024.
• Gross profit margin improved by 200 basis points to 32.0% in Q3 2025, driven by higher product pricing and lower distribution costs.
• Successful refinancing of Term B loans on March 6, 2025, which decreased interest rate margins by 25 basis points.
• Strategic acquisitions of ND Industries Asia, GEM S.r.l., Medifill Limited, and HS Butyl Limited are expected to accelerate growth in high-margin segments and expand market presence.
• Positive foreign currency impact of 1.0% on net revenue in Q3 2025.
• Interest expense decreased by 4.8% in Q3 2025 due to lower interest rates.
• Disclosure controls and procedures were evaluated as effective as of August 30, 2025.

Negatives

• Overall net revenue decreased by 2.8% in Q3 2025 and 2.5% for the first nine months of 2025.
• Sales volume decreased by 1.9% in Q3 2025 and 0.2% for the first nine months of 2025.
• Net income attributable to H.B. Fuller for the first nine months of 2025 decreased by 11.2% to $122.2 million compared to the prior year.
• Diluted EPS for the first nine months of 2025 fell by 9.0% to $2.21 compared to the prior year.
• Net cash provided by operating activities decreased significantly by 27.6% to $156.8 million for the first nine months of 2025.
• Free cash flow decreased by 40.2% to $62.2 million for the first nine months of 2025.
• Selling, general and administrative (SG&A) expenses increased as a percentage of net revenue in both Q3 (90 bps) and the first nine months (110 bps) of 2025, primarily due to higher compensation costs and acquisition impacts.
• Negative currency effect of 1.1% on net revenue for the first nine months of 2025.
• A loss of $1.5 million was recorded on the sale of the North American Flooring business.

Risks

• Exposure to foreign currency exchange rate fluctuations that may affect net investment in foreign subsidiaries, earnings, cash flows, and financial position.
• Changes in interest rates and prices of raw materials can impact financial performance.
• Credit risk exists in the event of nonperformance by counterparties for foreign currency forward exchange contracts and interest rate swap agreements.
• Restrictive covenants in credit agreements, if not met, could lead to renegotiation of credit lines and a significant increase in financing costs.
• Involvement in environmental investigations, clean-up activities, and administrative proceedings, including being identified as a potentially responsible party (PRP) under CERCLA.
• Ongoing lawsuits, claims, investigations, and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax, and employment matters.
• Asbestos-related litigation, while historically not having a material adverse effect, could negatively impact results of operations or cash flows in future periods if adverse developments or periodic settlements occur.
• A class action lawsuit (Rouse et al. v. H.B. Fuller Company et al.) regarding alleged defects in grout is pending, with the company currently unable to estimate any possible loss or range of possible losses.
• Financial statements rely on estimates and assumptions that could differ from actual results.

Future Outlook

Restructuring plans are expected to be completed during fiscal year 2026, with remaining costs spread across the next several fiscal quarters. Management believes cash flows from operating activities will be adequate to meet short-term and long-term liquidity and capital expenditure needs, and the company expects to have the ability to obtain both short-term and long-term debt for foreseeable financing needs. U.S. cash is anticipated to be sufficient for U.S. operations, capital spending, pension contributions, acquisitions, dividend payments, debt service, and share repurchases. There is no current intention or plan to repatriate indefinitely reinvested international earnings for U.S. operations. The company is evaluating the effect of new accounting pronouncements (ASU 2024-03, ASU 2023-09, ASU 2023-07) on its consolidated financial statements.

Management Comments

• We believe that cash flows from operating activities will be adequate to meet our short-term and long-term liquidity and capital expenditure needs.
• In addition, we believe we have the ability to obtain both short-term and long-term debt to meet our financing needs for the foreseeable future.
• Based on currently available information, we have concluded that these matters [environmental], individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.
• While we are unable to predict the outcome of these matters [other legal proceedings], we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including the asbestos litigation described in the following paragraphs, will not have a material adverse effect on our results of operations, financial condition or cash flow.
• The Company intends to vigorously defend itself against the claims outlined in this lawsuit [Rouse et al. v. H.B. Fuller Company et al.].

Industry Context

H.B. Fuller Company is actively pursuing a strategy of capital allocation to high-margin, high-growth market segments within the functional coatings, adhesives, sealants, and elastomer industry. This is evidenced by recent acquisitions in specialty and medical adhesives, such as ND Industries Asia, GEM S.r.l., and Medifill Limited. The divestiture of the North American Flooring business indicates a strategic portfolio optimization, shedding lower-growth or non-core assets. The focus on medical and engineering adhesives suggests a move towards specialized, higher-value applications, aligning with broader industry trends of innovation and differentiation.

Comparison to Industry Standards

• NA. The filing does not provide specific comparable company or industry benchmark data to assess results against global standards.

Corporate Governance

Legal Proceedings

• Environmental investigations and clean-up activities, with a recorded liability of $2.8 million as of August 30, 2025, which is not expected to have a material adverse effect.
• Asbestos-related lawsuits, with 7 claims settled for $369 thousand in the nine months ended August 30, 2025, which are not expected to have a material adverse effect.
• A class action lawsuit, Rouse et al. v. H.B. Fuller Company et al., concerning alleged grout defects, with mediation scheduled for October 21-22, 2025. The company is currently unable to estimate any possible loss, but expects the resolution not to have a material adverse effect.

Stakeholder Impact

• Shareholders: Experienced positive Q3 earnings and EPS growth, but year-to-date decline and reduced cash flow could be a concern. The share repurchase program continues to return capital, and strategic acquisitions aim for long-term value.
• Employees: Restructuring plans involve severance and related employee costs globally, indicating potential workforce adjustments.
• Customers: Acquisitions aim to expand solution offerings and market relevance, while the divestiture of the North American Flooring business may impact certain customer segments.
• Creditors: Debt refinancing and compliance with covenants indicate sound financial management, though the total debt to total capital ratio has slightly increased.
• Suppliers: Supplier finance programs are in place, offering flexibility to participating suppliers.

Next Steps

• Completion of restructuring plans during fiscal year 2026.
• Mediation session for the Rouse et al. v. H.B. Fuller Company et al. lawsuit on or around October 21 and 22, 2025.
• Evaluation of the effect of new accounting standards (ASU 2024-03, ASU 2023-09, ASU 2023-07) on consolidated financial statements.
• Continued monitoring of credit quality of derivative counterparties.
• Ongoing defense against the Rouse et al. lawsuit.

Key Dates

Recommendation

H.B. Fuller's Q3 2025 results show a strong rebound in net income and EPS, driven by improved gross margins and strategic portfolio adjustments through acquisitions and divestitures. The successful debt refinancing is also a positive. However, the year-to-date performance, particularly the significant decline in operating and free cash flow, and the overall revenue decrease, present a mixed financial picture. While the strategic direction towards higher-margin segments is sound, the execution and its impact on sustained profitability and cash generation need further monitoring. The ongoing restructuring and legal proceedings, though currently deemed non-material, add a layer of uncertainty. A 'Hold' recommendation is appropriate as investors should observe if the positive Q3 trends can be sustained and if cash flow generation improves in subsequent periods, validating the strategic shifts.

Keywords

adhesives, sealants, specialty chemicals, industrial materials, Q3 2025 earnings, financial results, acquisitions, divestiture, H.B. Fuller, FUL, SEC filing, 10-Q, gross margin, cash flow, debt refinancing, restructuring